Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state.

[1]  C. Vlachopoulos,et al.  Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. , 2007, International journal of cardiology.

[2]  A. Cucina,et al.  TIMP-2 modulates neointimal formation in experimental ePTFE arterial grafts. , 2007, The Journal of surgical research.

[3]  A. Baker,et al.  Suppression of Atherosclerotic Plaque Progression and Instability by Tissue Inhibitor of Metalloproteinase-2: Involvement of Macrophage Migration and Apoptosis , 2006, Circulation.

[4]  Leslie L. Clark,et al.  Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease , 2006, Circulation.

[5]  V. Chopra,et al.  Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. , 2006, American heart journal.

[6]  R. Schnabel,et al.  Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. , 2006, European heart journal.

[7]  P. Ducimetiere,et al.  Serum tissue inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arterial stiffness , 2005, Journal of hypertension.

[8]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[9]  C. Vlachopoulos,et al.  Acute Systemic Inflammation Increases Arterial Stiffness and Decreases Wave Reflections in Healthy Individuals , 2005, Circulation.

[10]  K. Bauer,et al.  Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[11]  G. Lip,et al.  Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. , 2005, The American journal of cardiology.

[12]  J. Stone,et al.  Metalloproteinase-2 and -9 in Giant Cell Arteritis: Involvement in Vascular Remodeling , 2005, Circulation.

[13]  T. Henry,et al.  Extracellular Proteases in Atherosclerosis and Restenosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[14]  G. Lip,et al.  Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension. , 2005, American Journal of Hypertension.

[15]  G. Lip,et al.  Tissue inhibitor of metalloproteinse‐1 is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertension , 2005, European journal of clinical investigation.

[16]  D. Levy,et al.  Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. , 2004, European heart journal.

[17]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[18]  A. Tedgui,et al.  Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[19]  A. Baker,et al.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. , 1998, The Journal of clinical investigation.

[20]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[21]  E. Howard,et al.  Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. , 1991, The Journal of biological chemistry.